Free Republic
Browse · Search
News/Activism
Topics · Post Article

Skip to comments.

Study of Tumor Recurrence May Change Drug Guidelines (for small HER2 positive breast cancer)
NY Times ^ | December 13, 2008 | TARA PARKER-POPE

Posted on 12/13/2008 10:20:49 PM PST by neverdem

A particularly fast-growing form of breast cancer should be treated aggressively after surgery even when tumors are very small, according to new research that could alter treatment for one in five women diagnosed with breast cancer.

The research, reported Friday at the San Antonio Breast Cancer Symposium, focuses on the 15 percent to 20 percent of women with breast cancer who test positive for an amplification of the HER2 gene, which is typically among the most aggressive forms of the disease.

Today, a targeted therapy called Herceptin, made by the biotech company Genentech, has greatly improved the odds for women with HER2-positive cancer. Recent studies show the drug reduces the recurrence of these cancers by about half.

But current treatment guidelines do not recommend that the drug be given to women with HER2-positive tumors less than one-half centimeter in size. The guidelines also suggest only that doctors discuss Herceptin treatment with women who have tumors between one-half and one centimeter in size.

Researchers at the University of Texas M.D. Anderson Cancer Center reviewed data from 965 women treated from 1990 to 2002 who had tumors less than one centimeter in size. They also studied 350 patients from European institutions.

They found that after five years, 23 percent of women with very small HER2-positive tumors experienced a return of the cancer, compared with 6 percent of similar women without HER2 disease. The finding indicates that even among women who detect their cancers early, the risk of recurrence is nearly three times greater if they test positive for HER2 than if they do not. None of the women in the study received Herceptin treatment.

Although the data on recurrence strongly suggest that women with early-stage HER2-positive cancer could benefit from aggressive treatment, the study did not examine the effectiveness of Herceptin in...

(Excerpt) Read more at nytimes.com ...


TOPICS: Culture/Society; News/Current Events; Testing
KEYWORDS: breastcancer; her2; herceptin; medicine

1 posted on 12/13/2008 10:20:49 PM PST by neverdem
[ Post Reply | Private Reply | View Replies]

To: neverdem

I had to stop Herceptin. It gave me a heart attack. It’s a dangerous drug. If you have any heart disease in your family it may not be worth the risk. Within 3 doses I could feel my heart weakening. Not good.

They need to keep trying to find better drugs with fewer side effects.


2 posted on 12/13/2008 10:26:04 PM PST by deannadurbin
[ Post Reply | Private Reply | To 1 | View Replies]

To: neverdem

Bump for tomorrow...


3 posted on 12/13/2008 10:49:16 PM PST by tubebender (Retirement...The art and science of Killing time before it Kills you...)
[ Post Reply | Private Reply | To 1 | View Replies]

To: neverdem

bump for easy location to read later.... as I am going in for ‘follow-up’ testing....hmmmm

I may be in need of some relitive reading material....


4 posted on 12/13/2008 10:55:14 PM PST by bellas_sister ("Have you seen the price of arugula at Whole Foods?")
[ Post Reply | Private Reply | To 1 | View Replies]

To: neverdem

bookmark


5 posted on 12/13/2008 11:32:21 PM PST by GOP Poet
[ Post Reply | Private Reply | To 1 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
News/Activism
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson